These results suggest that KRT17 may affect tumour growth through Akt/EMT signaling pathway and a biomarker for the diagnosis and prognosis of ESCC, which provides evidence for guiding the treatment of esophageal cancer patients (Liu et al., 2020). This evidence concerns the gene AKT1 and esophageal squamous cell carcinoma.